• FibroBiologics expanded its fibroblast therapy portfolio to 170 issued patents, up from 124 on Dec. 31, 2025.
• The portfolio now exceeds 325 issued and pending patents worldwide, spanning more than 50 patent families.
• U.S. patents granted in 2026 cover wound healing, type 1 diabetes and other diseases.
• European grants protect methods to enhance fibroblast therapeutic activity and deliver tumor-inhibiting agents.
• More than 150 applications remain pending, with recent filings covering injectable thymus organoids, therapeutic peptide-producing cell aggregates and oral fibroblast therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611120830PR_NEWS_USPR_____DA95996) on November 12, 2026, and is solely responsible for the information contained therein.